Exposure Seeds

Occupational radiation exposure from brachytherapy seeds is dependent on the dose rate from the seeds and the manner in which they are handled and shielded. Short-lived Cs-131 and Pd-103 seeds deliver a therapeutic dose in a much shorter time than I-125. The shorter half-life has radiobiological advantages that are beneficial to the patient.

The dose rate from exposed seeds is measured in Air Kerma Strength (Sk). Air Kerma Strength is measured in terms of rads/hour at 1 cm from the source (U).

The total Air Kerma strength for a given brachytherapy case can be determined from nomograms developed for each isotope. These nomograms allow one to estimate the total Air Kerma strength required based on the volume of the prostate. Prostate volumes can vary from less than 20 cc to greater than 70 cc, but typically will be in the range of 40 cc to 50 cc. Taking 40 cc as an example the total case Air Kerma strength at the time of implant for each of the three isotopes would be approximately:

- I-125: 40 U (145 Gy prescribed dose)
- Pd-103: 205 U (125 Gy prescribed dose)
- Cs-131: 142 U (115 Gy prescribed dose)

Both Cs-131 and Pd-103 require the clinician to pay more attention to shielding and time of exposure than does I-125. However, based on years of clinical experience, both can be handled safely in routine clinical practice.

Dose from a patient after Cs-131 implant

Patients implanted with I-125 and Pd-103 seeds will give off lower dose rates than Cs-131 on the day of implant due to the lower Air Kerma strength of I-125, and the greater absorption in tissue of the radiation from Pd-103, despite the higher total Air Kerma per case for Pd-103.

Health care providers can expect to see a dose rate at one meter from a typical Cs-131 patient of approximately 2 mrad/hr. This depends on patient weight and the total Air Kerma strength of the implant. Thin patients with large prostates will deliver higher dose rates.

Patient Release Criteria

The criteria to be considered in determining patient release are delineated in Appendix U of NUREG 1556, Vol. 95 and NCRP Report No. 37, chapter 4, “Release from Hospital of Patients Containing Radioactive Material.” Since Cs-131 is not explicitly listed in Table U1 of NUREG 1556 or in NCRP Report No. 37, special instructions are required. Note that NUREG 1556, Vol. 9 Appendix U uses the assumption that measured dose rate is essentially a measurement of Effective Dose Equivalent (EDE) rate. At the energies of low dose rate brachytherapy sources measured dose rate greatly overestimates EDE. An example calculation is attached as Appendix A. The specific patient release instructions should be based on the implanting facility’s protocol and/or the Doctor’s instructions given to his/her patient. Isoray’s policy is not to dictate what should or should not be included in patient release instructions, but to provide information and guidelines regarding Cs-131 that are helpful in counseling patients about radiation safety following a Cs-131 implant.
The NUREG guidance permits an occupancy factor of 0.25 at one meter from the patient to be used in estimating the dose to a maximally exposed individual, usually a spouse. With an allowable exposure of 500 mrad, the allowable dose rate from a Cs-131 patient on day 0 is 6 mrad/hr.

\[
333 \text{ hours x 6 mrad/hr x 0.25} = 500 \text{ mrad} \quad \text{(see NUREG 1556 Equation U.1)}
\]

Thus, patients may be released at or below 6 mrad/hr, with instructions. (The highest dose rate at one meter that Isoray is aware of from a 131Cs implant patient is 4 mrad/hr.)

Another approach to instructions for patient release is to directly compare the expected dose to a family member from I-125 or Cs-131. Since I-125 is prescribed at 145 Gy and Cs-131 is prescribed at 115 Gy, and the energy of the radiation from both isotopes is similar, the dose to a family member will be proportional to the prescribed dose. Given similar behaviors of the patient and family, over time, an I-125 implant will result in approximately 25% higher total dose to the family member than a Cs-131 implant.

Note: Attention should be given to the type of survey instrument used to make patient release determinations. Many GM survey instruments over-respond significantly to the radiation from both I-125 and Cs-131, but respond fairly accurately to Pd-103. It is best to use a properly calibrated thin window ion chamber or equivalent to measure the dose rate from a Cs-131 implant.

---

**General Precautions to be Addressed with the Patient**

Travel and contact with small children or pregnant women can occur, but they should remain 3-6 feet from the patient and be limited to a maximum of 5 minutes per day. Children should not sit on the patient’s lap during the first 15 days following a Cs-131 implant. A patient’s spouse may sleep in the same bed if there is no risk of pregnancy. Sexual intercourse may resume within a few weeks post-implant. Very occasionally, a seed can be expelled in the semen on ejaculation. If this does happen, it will usually occur in the first few ejaculations; therefore it is advisable to use a condom for the first two or three occasions of intercourse following implant.

Patients can usually get back to normal activities and work within a few days. Follow up medical examination is recommended after four to six weeks, and then every three months for a year, every six months up to five years, and then annually.

For additional questions regarding Cs-131 radiation safety please contact Isoray Radiation Safety Officer at 509-375-1202.

---

**References**

5. U.S. NRC, Release of Patients Administered Radioactive Materials, NUREG 1556, Vol. 9, Appendix U.
6. Precautions in the management of Patients Who Have Received Therapeutic Amounts of Radionuclides, NCRP Report 37, Washington DC (1970)